Epstein Secrets

evices suitable f=r working in developing countries, and may be powered and run by a cell phone or smart device. • Current CDC approved EZ1-RT-P=R Taqman assay has LOD of 5,000 PFU/ml. This works when patient is&nbs=;febrile, i.e. has overt symptoms and may be contagious. • Next level of assay needs

= Frederick, MD. 4. Integrated Research Facility, Division of Clinical Research, N=AID, NIH, Ft. Detrick, MD 2 EFTA_R1_01432418 EFTA02398448 5. Poxvirus Team, Poxvirus and Rabies Branch, Division of High Conseque=ce Pathogens and Pathology, National Center of Emerging Zoonotic a=d Infectious Diseases, Cen

ricated devices that w=ll allow for electronic detection, obviating the need for expens=ve hardware used in most fluorescent detection schemes (i.e. Taqman a=says). As such, we are poised to combine these technologie= for rapidly identifying and providing quantitative viral load fo= all the VHF, Variol

rch Institute of Infectious Disease=, Frederick, MD. 4. Integrated Research Facility, Division of Clinical Research, =IAID, NIH, Ft. Detrick, MD 5. Poxvirus Team, Poxvirus and Rabies Branch, Division of High Consequ=nce Pathogens and Pathology, National Center of Emerging Zoonoti= and Infectious Diseases, Cen

devices suitable f=r working in developing countries, and may be powered and run by a cell phone or smart device. • Current CDC approved EZ1-RT-P=R Taqman assay has LOD of 5,000 PFU/ml. This works when patient is&nbs=;febrile, i.e. has overt symptoms and may be contagious. • Next level of assay needs

rch Institute of Infectious Diseases= Frederick, MD. 4. Integrated Research Facility, Division of Clinical Research, N=AID, NIH, Ft. Detrick, MD 5. Poxvirus Team, Poxvirus and Rabies Branch, Division of High Conseque=ce Pathogens and Pathology, National Center of Emerging Zoonotic a=d Infectious Diseases, Cen